Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Opipramol→

Opipramol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
315-72-0
Molecular formula
C23H29N3O
Molecular weight
363.5 g/mol
Drug class
Tricyclic-structure anxiolyticsigma-1 and sigma-2 receptor ligand
Mechanism of action
Unlike conventional tricyclic antidepressants, opipramol has relatively low monoamine-reuptake inhibition and acts predominantly through sigma-1 and sigma-2 receptor interactions, with additional affinity for histamine H1 and other central receptors. These effects modulate central anxiety and somatic symptom pathways.
Indications / reported uses
  • Treatment of generalised anxiety disorder and somatoform disorders in countries where opipramol is authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=opipramol+sigma+receptor+mechanism · https://pubchem.ncbi.nlm.nih.gov/#query=opipramol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Opipramol Environmental Risk Assessment (ERA) (the Opipramol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.